News
GNFTY
8.80
NaN%
--
Weekly Report: what happened at GNFTY last week (0302-0306)?
Weekly Report · 03/09 10:23
Weekly Report: what happened at GNFTY last week (0223-0227)?
Weekly Report · 03/02 10:22
Weekly Report: what happened at GNFTY last week (0216-0220)?
Weekly Report · 02/23 10:22
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Seeking Alpha · 02/20 19:24
Weekly Report: what happened at GNFTY last week (0209-0213)?
Weekly Report · 02/16 10:22
Genfit adds $20M as Ipsen records strong sales for liver drug
Seeking Alpha · 02/12 18:52
Weekly Report: what happened at GNFTY last week (0202-0206)?
Weekly Report · 02/09 10:24
Weekly Report: what happened at GNFTY last week (0126-0130)?
Weekly Report · 02/02 10:23
Weekly Report: what happened at GNFTY last week (0119-0123)?
Weekly Report · 01/26 10:23
Weekly Report: what happened at GNFTY last week (0112-0116)?
Weekly Report · 01/19 10:30
Genfit Advances Liver Pipeline With Completed Phase 1 G1090N Study
TipRanks · 01/16 16:30
Gilead Sciences: From All-Time Highs To Higher Highs
Seeking Alpha · 01/12 22:40
Weekly Report: what happened at GNFTY last week (0105-0109)?
Weekly Report · 01/12 10:29
Kepler Capital Remains a Buy on Genfit (GNFTF)
TipRanks · 01/09 01:37
Weekly Report: what happened at GNFTY last week (1229-0102)?
Weekly Report · 01/05 10:22
Weekly Report: what happened at GNFTY last week (1222-1226)?
Weekly Report · 12/29/2025 10:22
Weekly Report: what happened at GNFTY last week (1215-1219)?
Weekly Report · 12/22/2025 10:22
Weekly Report: what happened at GNFTY last week (1208-1212)?
Weekly Report · 12/15/2025 10:29
Weekly Report: what happened at GNFTY last week (1201-1205)?
Weekly Report · 12/08/2025 10:28
Weekly Report: what happened at GNFTY last week (1124-1128)?
Weekly Report · 12/01/2025 10:23
More
Webull provides a variety of real-time GNFTY stock news. You can receive the latest news about Genfit S.A. through multiple platforms. This information may help you make smarter investment decisions.
About GNFTY
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.